Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorVolkan İnce
dc.contributor.authorSami Akbulut
dc.contributor.authorEmrah Otan
dc.contributor.authorVeysel Ersan
dc.contributor.authorSerdar Karakaş
dc.contributor.authorTolga Tevfik Şahin
dc.contributor.authorBrian I Carr
dc.contributor.authorAdil Baskiran
dc.contributor.authorEmine Şamdancı
dc.contributor.authorHarika Gözükara Bağ
dc.contributor.authorCemalettin Koç
dc.contributor.authorSertaç Usta
dc.contributor.authorFatih Özdemir
dc.contributor.authorBora Barut
dc.contributor.authorFatih Gönültas
dc.contributor.authorBarış Sarıcı
dc.contributor.authorKoray Kutluturk
dc.contributor.authorMurat Sait Dogan
dc.contributor.authorDinçer Özgör
dc.contributor.authorMustafa Dikilitaş
dc.contributor.authorMurat Harputluoglu
dc.contributor.authorMurat Aladağ
dc.contributor.authorRamazan Kutlu
dc.contributor.authorIlknur Varol
dc.contributor.authorAbuzer Dirican
dc.contributor.authorCemalettin Aydın
dc.contributor.authorBurak Işık
dc.contributor.authorCengiz Ara
dc.contributor.authorCüneyt Kayaalp
dc.contributor.authorŞükrü Emre
dc.contributor.authorSezai Yılmaz
dc.date.accessioned2022-05-06T07:16:09Z
dc.date.available2022-05-06T07:16:09Z
dc.date.issued2020en_US
dc.identifier.citationInce, V., Akbulut, S., Otan, E., Ersan, V., Karakas, S., Sahin, T. T., ... & Yilmaz, S. (2020). Liver transplantation for hepatocellular carcinoma: Malatya experience and proposals for expanded criteria. Journal of Gastrointestinal Cancer, 51(3), 998-1005.en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00424-w
dc.identifier.urihttps://hdl.handle.net/20.500.12899/1067
dc.description.abstractSurvival was examined from a Turkish liver transplant center of patients with HCC, to identify prognostic factors. Data from 215 patients who underwent predominantly live donor liver transplant for HCC at our institute over 12 years were included in the study and prospectively recorded. They were 152 patients within and 63 patients beyond Milan criteria. Patients beyond Milan criteria were divided into two groups according to presence or absence of tumor recurrence. Recurrence-associated factors were analyzed. These factors were then applied to the total cohort for survival analysis. We identified four factors, using multivariate analysis, that were significantly associated with tumor recurrence. These were maximum tumor diameter, degree of tumor differentiation, and serum AFP and GGT levels. A model that included all four of these factors was constructed, the ‘Malatya criteria.’ Using these Malatya criteria, we estimated DFS and cumulative survival, for patients within and beyond these criteria, and found statistically significant differences with improved survival in patients within Malatya criteria of 1, 5, and 10-year overall survival rates of 90.1%, 79.7%, and 72.8% respectively, which compared favorably with other extra-Milan extended criteria. Survival of our patients within the newly defined Malatya criteria compared favorably with other extra-Milan extended criteria and highlight the usefulness of serum AFP and GGT levels in decision-making.en_US
dc.language.isoenen_US
dc.publisherMurat Aladagen_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepaticen_US
dc.subjectMalignancyen_US
dc.subjectLive donoren_US
dc.subjectMalatya criteriaen_US
dc.titleLiver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteriaen_US
dc.typeArticleen_US
dc.authorid0000-0002-4563-7027en_US
dc.departmentMTÖ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.institutionauthorAladağ, Murat
dc.identifier.doi10.1007/s12029-020-00424-w
dc.identifier.volume51en_US
dc.identifier.startpage998en_US
dc.identifier.endpage1005en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster